Efficacy of Tumour Necrosis Factor-alpha therapy in paediatric Crohn’s disease patients with perianal lesions: a systematic review

References

• Schwartz DA, Loftus EV Jr., Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr;122(4):875–880.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology. 2006 Mar;130(3):650–656.
   PubMed Web of Science ®Google Scholar
• Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008 Aug;43(8):948–954.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol. 2012 Aug 7;18(29):3806–3813.
   PubMed Web of Science ®Google Scholar
• Lionetti HJ, Oh SH, Kim DY, et al. Clinical characteristics and long-term outcomes of paediatric Crohn’s disease: a single-centre experience. J Crohns Colitis. 2017 Feb;11(2):157–164.
   PubMed Web of Science ®Google Scholar
• Assa A, Amitai M, Greer ML, et al. Perianal pediatric Crohn disease is associated with a distinct phenotype and greater inflammatory burden. J Pediatr Gastroenterol Nutr. 2017 Sep;65(3):293–298.
   PubMed Web of Science ®Google Scholar
• Panes J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):652–664.
   PubMed Web of Science ®Google Scholar
• Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn’s disease. Inflamm Bowel Dis. 2009 Mar;15(3):383–387.
   PubMed Web of Science ®Google Scholar
• TW E, Roberts R, Pearson J, et al. Clinical and genetic risk factors for perianal Crohn’s disease in a population-based cohort. Am J Gastroenterol. 2012 Apr;107(4):589–596.
   PubMed Web of Science ®Google Scholar
• de Zoeten EF, Pasternak BA, Mattei P, et al. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr. 2013 Sep;57(3):401–412.
   PubMed Web of Science ®Google Scholar
• Zwintscher NP, Shah PM, Argawal A, et al. The impact of perianal disease in young patients with inflammatory bowel disease. Int J Colorectal Dis. 2015 Sep;30(9):1275–1279.
   PubMed Web of Science ®Google Scholar
• Mahadev S, Young JM, Selby W, et al. Self-reported depressive symptoms and suicidal feelings in perianal Crohn’s disease. Colorectal Dis. 2012 Mar;14(3):331–335.
   PubMed Web of Science ®Google Scholar
• Greenley RN, Hommel KA, Nebel J, et al. A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease. J Pediatr Psychol. 2010 Sep;35(8):857–869.
   PubMed Web of Science ®Google Scholar
• Mackner LM, Crandall WV. Psychological factors affecting pediatric inflammatory bowel disease. Curr Opin Pediatr. 2007 Oct;19(5):548–552.
   PubMed Web of Science ®Google Scholar
• Mackner LM, Crandall WV. Long-term psychosocial outcomes reported by children and adolescents with inflammatory bowel disease. Am J Gastroenterol. 2005 Jun;100(6):1386–1392.
   PubMed Web of Science ®Google Scholar
• Mackner LM, Crandall WV, Szigethy EM. Psychosocial functioning in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006 Mar;12(3):239–244.
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007 Mar;132(3):863–873. quiz 1165-6.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012 Aug;143(2):365–74.e2.
   PubMed Web of Science ®Google Scholar
• Dupont-Lucas C, Dabadie A, Alberti C, et al. Predictors of response to infliximab in paediatric perianal Crohn’s disease. Aliment Pharmacol Ther. 2014 Oct;40(8):917–929.
   PubMed Web of Science ®Google Scholar
• de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr. 2004 Jul;39(1):46–52.
   PubMed Web of Science ®Google Scholar
• Seemann NM, King SK, Elkadri A, et al. The operative management of children with complex perianal Crohn’s disease. J Pediatr Surg. 2016;51(12):1993–1997.
   PubMed Web of Science ®Google Scholar
• Prospero international prospective register of systematic reviews. [cited 2018 Oct 2]. Available from: https://www.crd.york.ac.uk/PROSPERO/
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 Aug 18;151(4):264–269. w64.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000 Apr 19;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2019 Feb 2]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998 Jun;52(6):377–384.
   PubMed Web of Science ®Google Scholar
• NIH study quality assessment tools. [cited 2018 Dec 20]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
   Google Scholar
• Ruemmele FM, Lachaux A, Cezard JP, et al. Efficacy of infliximab in pediatric Crohn’s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis. 2009 Mar;15(3):388–394.
   PubMed Web of Science ®Google Scholar
• Kierkus J, Iwanczak B, Wegner A, et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr. 2015 May;60(5):580–585.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Rosh J, Faubion WA, et al. Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn’s disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018 Nov 9;12(10):1249–1254.
   PubMed Web of Science ®Google Scholar
• Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):183–190.
   PubMed Web of Science ®Google Scholar
• Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn’s disease. Am J Gastroenterol. 2009 Oct;104(10):2566–2571.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Lee JS, Lee JH, et al. Infliximab therapy in children with Crohn’s disease: a one‐year evaluation of efficacy comparing ‘top‐down’and ‘step‐up’strategies. Acta Paediatrica. 2011;100:451–455.
   PubMed Web of Science ®Google Scholar
• Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2003 Aug 15;18(4):425–431.
   PubMed Web of Science ®Google Scholar
• Hukkinen M, Pakarinen MP, Piekkala M, et al. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn’s disease. J Crohns Colitis. 2014 Aug;8(8):756–762.
   PubMed Web of Science ®Google Scholar
• Iwanczak BM, Ryzko J, Jankowski P, et al. Induction and maintenance infliximab therapy for the treatment of Crohn’s disease with perianal fistulas in children: retrospective, multicenter study. Adv Clin Exp Med. 2016 May–Jun;25(3):523–530.
   PubMed Web of Science ®Google Scholar
• Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2003 May;36(5):632–636.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr. 2000 Aug;137(2):192–196.
   PubMed Web of Science ®Google Scholar
• Sinitsky DM, Lemberg DA, Leach ST, et al. Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol. 2010 Apr;25(4):810–816.
   PubMed Web of Science ®Google Scholar
• Sykora J, Huml M, Siala K, et al. Fistulizing anorectal Crohn disease in a child with severe HLA-B27-associated enthesitis-related arthritis. J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):491–494.
   PubMed Web of Science ®Google Scholar
• Akman SA, Arikan C, Sozen G, et al. Infliximab treatment of pediatric refractory Crohn’s disease: a case report. Turk J Gastroenterol. 2006 Jun;17(2):133–136.
   PubMedGoogle Scholar
• Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Apr;33(8):946–953.
   PubMed Web of Science ®Google Scholar
• Munoz Urribarri A, Sylvester F, Delgado Godos A, et al. Management of colonic Crohn disease with no response to corticoids and sulfazalazine: first case of pediatric use of infliximab in Peru. Rev Gastroenterol Peru. 2013 Apr–Jun;33(2):162–166.
   PubMedGoogle Scholar
• Barabino A, Castellano E, Gandullia P, et al. A girl with severe fistulizing Crohn’s disease. Dig Liver Dis. 2000 Dec;32(9):792–794.
   PubMedGoogle Scholar
• Rosenbach Y, Hartman C, Shapiro R, et al. Adalimumab treatment in children with refractory Crohn’s disease. Dig Dis Sci. 2010 Mar;55(3):747–753.
   PubMed Web of Science ®Google Scholar
• Singer AA, Gadepalli SK, Eder SJ, et al. Fistulizing Crohn’s disease presenting after surgery on a perianal lesion. Pediatrics. 2016 Mar;137(3):e20152878.
   PubMed Web of Science ®Google Scholar
• Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother. 2001 Jul–Aug;35(7–8):823–828.
   PubMed Web of Science ®Google Scholar
• Uslu N, Usta Y, Saltik-Temizel IN, et al. Ineffectiveness of infliximab therapy in severe infantile Crohn’s disease. J Crohn’s Colitis. 2010;4(1):106–109.
   Google Scholar
• Saadah OI. Anti-TNFalpha antibody infliximab treatment for an infant with fistulising Crohn’s disease. BMJ Case Rep. 2010;2010:bcr04.2009.1739.
   Google Scholar
• Gouldthorpe O, Catto-Smith AG, Alex G, et al. Loss of response to long-term infliximab therapy in children with Crohn’s disease. Pharmaceuticals (Basel). 2013 Oct 16;6(10):1322–1334.
   PubMedGoogle Scholar
• Eradi B, Sandhu BK, Spray C, et al. Highly destructive perianal crohn disease. J Pediatr Gastroenterol Nutr. 2005 Nov;41(5):667–669.
   PubMed Web of Science ®Google Scholar
• Bicette R, Tenjarla G, Kugathasan S, et al. A 14-year-old girl with recurrent vulvar abscess. J Pediatr Adolesc Gynecol. 2014 Aug 1;27(4):e83–e86.
   PubMedGoogle Scholar
• Cozijnsen MA, van Pieterson M, Samsom JN, et al. Top-down infliximab study in kids with Crohn’s disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol. 2016;3(1):e000123.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s Colitis. 2016 Sep 22;11(1):3–25.
   Google Scholar
• Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–948.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1127–1136.
   PubMed Web of Science ®Google Scholar
• Zhang QW, Shen J, Zheng Q, et al. Loss of response to scheduled infliximab therapy for Crohn’s disease in adults: a systematic review and meta-analysis. J Dig Dis. 2019 Feb;20(2):65–72.
   PubMed Web of Science ®Google Scholar
• Adegbola SO, Sahnan K, Warusavitarne J, et al. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci. 2018;19(8):2244.
   Web of Science ®Google Scholar
• Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb;106(2):214–223. quiz 224.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Guerra I, Muñoz‐Linares P, et al. Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012 May 1;35(9):971–986.
   PubMed Web of Science ®Google Scholar
• Tandon P, Rhee GG, Schwartz D, et al. Strategies to optimize anti-tumor necrosis factor therapy for perianal fistulizing Crohn’s disease: a systematic review. Dig Dis Sci. 2019 Apr;27:1–2.
   Google Scholar
• Yassin NA, Askari A, Warusavitarne J, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn’s disease. Aliment Pharmacol Ther. 2014;40(7):741–749.
   PubMed Web of Science ®Google Scholar
• Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med. 2005;142(12_Part_2):1090–1099.
   PubMed Web of Science ®Google Scholar
• Veereman-Wauters G, de Ridder L, Veres G, et al. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary. J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):830–837.
   PubMed Web of Science ®Google Scholar
• De Ridder L, Turner D, Wilson DC, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. Inflamm Bowel Dis. 2014 Feb;20(2):291–300.
   PubMed Web of Science ®Google Scholar
• Navas-Lopez VM, Blasco-Alonso J, Giron-Fernandez-Crehuet F, et al. Efficacy and safety of adalimumab in the treatment of Crohn s disease in children. Rev Esp Enferm Dig. 2013 Nov–Dec;105(10):579–584.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443–1451. quiz e88-9.
   PubMed Web of Science ®Google Scholar
• Cozijnsen MA, Samsom JN, de Ridder L. Anti-tumour necrosis factor Therapy for paediatric Crohn’s disease: improved benefits through treatment optimisation, deeper understanding of its risks, and reduced costs due to biosimilar availability. Paediatr Drugs. 2018 Feb;20(1):19–28.
   PubMed Web of Science ®Google Scholar